A study related to usability of Mesalazine Controlled-Release Tablets and Granules.

A study related to usability of Mesalazine Controlled-Release Tablets and Granules. - A study related to usability of Mesalazine Controlled-Release Tablets and Granules.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022954

Enrollment

Registered

2016-07-05

Start date

2016-01-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ulcerative colitis

Interventions

Patients take Mesalazine Controlled-release tablets at first, 3-12 weeks, then take granules, 3-12 weeks Patients take Mesalazine Controlled-release granules at first, 3-12 weeks, then take tablets, 3

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.patients who are considered to be appropriate to take mesalazine controlled-release tablets and granules 2.patients who considered to be able to evaluate usability of medication 3.patients from whom written informed consent was obtained

Exclusion criteria

Exclusion criteria: Patients who do not meet the above criteria

Design outcomes

Primary

Measure	Time frame
Differences in usability between Mesalazine Controlled-Release Tablets and Granules(by questionnaire)	—

Secondary

Measure	Time frame
adherence(by questionnaire) changes in subjective symptoms,concomitant medications, Lichtiger Score, Mayo Score occurence of side effect (during the period of taking tablets or granules)	—

Countries

Japan

Contacts

Public ContactKeiji Yagisawa

Kitasato University Kitasato Institute Hospital Kitasato University Kitasato Institute Hospital

k-yagi@insti.kitasato-u.ac.jp03-3444-6161

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026